Sight Sciences, Inc.
About Sight Sciences, Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $77.4M
- Net income
- -$38.4M
- Total assets
- $115.3M
- Market cap
- $242.1M
- Gross margin
- 86.2%
- Operating margin
- -48.0%
- Net margin
- -49.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $77.4M
- Cost of revenue
- $10.7M
- Gross profit
- $66.7M
- Operating expenses
- $103.8M
- Operating income
- -$37.1M
- Income tax
- $10.0K
- Net income
- -$38.4M
- EPS (basic)
- $-0.74
- EPS (diluted)
- $-0.74
Balance sheet
- Total assets
- $115.3M
- Current assets
- $112.7M
- Total liabilities
- $51.4M
- Current liabilities
- $11.0M
- Shareholders’ equity
- $63.9M
Cash flow
- Operating cash flow
- -$29.7M
- Investing cash flow
- -$224.0K
- Financing cash flow
- $1.8M
- Net cash flow
- -$28.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $242.1M
- EPS (diluted)
- $-0.74
- Shares outstanding
- 52.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 15, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $38.4M in FY2025.
- Revenue grew 58% from FY2021 to FY2025.
- Gross margin of 86.2%, net margin -49.7%.
- Trading 49% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Sight Sciences, Inc..
Write a review
News about Sight Sciences, Inc.
News & sentiment via Polygon.io
